Actineer Inc. was founded in 2023 by ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL), which manages and operates the national laboratory at Chalk River, Ontario, on behalf of Atomic Energy of Canada Limited (AECL).
As a rare alpha emitting medical isotope, Ac-225 is gaining increasing attention across the precision oncology field due to its significant potential as a powerful new potential weapon in the fight against cancer.
Plenty of radiopharmaceutical companies included Ac-225-based molecules as lead program to their pipeline already being well advanced in some cases and requiring this radioisotope as starting material on-time in-full.
The joint venture’s overall goal is to fulfill the unmet global needs of Actinium-225 in order to ensure a reliable supply urgently needed for next generation radiopharmaceuticals and patients worldwide.
Actineer Inc. is a new joint venture for industrial scale production of Actinium-225
If you want to take the initiative, please send us your full application.
No jobs found.